Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharming Group (PHAR)
NASDAQ:PHAR
PHAR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.65 - $13.20
Previous CloseN/A
Volume181.00
Average Volume (3M)6.98K
Market Cap
$619.89M
Enterprise Value$514.96M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Mar 13, 2025EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding67,835,434
10 Day Avg. Volume6,303
30 Day Avg. Volume6,977
Standard Deviation0.14
R-Squared0.00082
Alpha0.00068
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.49
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$25.50Price Target Upside187.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
AcquisitionPharming builds on rare disease expertise with proposed acquisition of Abliva, which has received unanimous approval from Abliva’s board and acceptance commitments from its three largest shareholders.
Financial ResourcesPharming has enough available cash and future cash flows to fund both the acquisition and future development and early commercialization costs of Abliva's lead candidate, KL1333.
Product LaunchJoenja's launch is strong with an increasing number of patients on paid therapy, indicating its importance as a growth driver for Pharming.
Bears Say
Complex ProcessesThere have been no insurance rejections for Joenja in getting patients on paid therapy, though some of the processes were more complex.
Management ChangeCEO Sijmen de Vries has announced that after 16 years as CEO, he informed the board that he will not seek reappointment to the position.
Regulatory ChallengesJoenja's global reach is expanding, with approvals in the U.S., Israel, and the U.K., and ongoing regulatory reviews in the E.U, Canada, and Australia.
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
0.06% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHAR FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was $6.65 and its highest was $13.20 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is $619.89M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Mar 13, 2025 which is in 34 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Oct 24, 2024. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.002 by -$0.018.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Undervalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is 0.02.
How many shares outstanding does Pharming Group have?
Pharming Group has 67,835,434 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.002. Following the earnings report the stock price went down -7.366%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in PHAR
---
Pharming Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.50 (187.49% Upside)
$25.50 (187.49% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.00%
12-Months-Change
Fundamentals
Return on Equity
-7.98%
Trailing 12-Months
Asset Growth
-2.51%
Trailing 12-Months
Company Description
Pharming Group
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on the development and production of human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. Most of the revenue generated from the United States.
---
PHAR Company Deck
---
PHAR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in RUCONEST and Joenja sales, along with strategic developments such as the new Phase II trial. However, the company faced a net loss due to increased operating expenses and financial challenges. Overall, the positive revenue trends and strategic progress were balanced by financial challenges, indicating a mixed outlook.Read More>---
PHAR Stock 12 Month Forecast
Average Price Target
$25.50
▲(187.49% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Biogen
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Best Analysts Covering PHAR
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-14.34%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -14.34% per trade.
---